troglitazone has been researched along with Disease Exacerbation in 13 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the therapeutic effects of the peroxisome proliferator-activated receptor (PPAR) gamma activating ligand, troglitazone, in patients with refractory metastatic breast cancer." | 9.10 | Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. ( Burstein, HJ; Demetri, GD; Mueller, E; Sarraf, P; Spiegelman, BM; Winer, EP, 2003) |
| "We have previously reported that troglitazone inhibits proinflammatory cytokine production in chronic pancreatitis." | 7.72 | Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPARgamma-independent mechanism. ( Kawamata, H; Kobayashi, M; Shimizu, K; Shiratori, K, 2004) |
| "A 68-year-old woman, with type 2 diabetes mellitus, hypercholesterolemia, and prior long-term simvastatin therapy, self-resumed troglitazone after running out of metformin." | 7.71 | Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. ( Caldwell, SH; Hespenheide, EE; von Borstel, RW, 2001) |
| "We analyzed data from the Diabetes Prevention Program (DPP) for 2,476 adults in 1996-1999 with prediabetes randomized to receive treatment with lifestyle modification, metformin, or placebo for 2-3 years and followed through 2014 for T2DM and CVD outcomes." | 5.27 | Use of a Metabolic Syndrome Severity ( DeBoer, MD; Filipp, SL; Gurka, MJ, 2018) |
| "To evaluate the therapeutic effects of the peroxisome proliferator-activated receptor (PPAR) gamma activating ligand, troglitazone, in patients with refractory metastatic breast cancer." | 5.10 | Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. ( Burstein, HJ; Demetri, GD; Mueller, E; Sarraf, P; Spiegelman, BM; Winer, EP, 2003) |
| "We have previously reported that troglitazone inhibits proinflammatory cytokine production in chronic pancreatitis." | 3.72 | Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPARgamma-independent mechanism. ( Kawamata, H; Kobayashi, M; Shimizu, K; Shiratori, K, 2004) |
| "A 68-year-old woman, with type 2 diabetes mellitus, hypercholesterolemia, and prior long-term simvastatin therapy, self-resumed troglitazone after running out of metformin." | 3.71 | Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. ( Caldwell, SH; Hespenheide, EE; von Borstel, RW, 2001) |
| "Women with a history of gestational diabetes mellitus (GDM) are at increased risk of future development of type 2 diabetes." | 1.39 | Prediction of type 2 diabetes in women with a history of gestational diabetes using a genetic risk score. ( Cho, NH; Cho, YM; Choi, SH; Jang, HC; Jung, HS; Kim, K; Kim, SY; Kwak, SH; Lim, S; Park, KS, 2013) |
| "Diabetic nephropathy is characterized functionally by glomerular hyperfiltration and albuminuria and histologically by the expansion of glomerular mesangium." | 1.31 | Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway. ( Haneda, M; Kikkawa, R; Koya, D, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (84.62) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| DeBoer, MD | 1 |
| Filipp, SL | 1 |
| Gurka, MJ | 1 |
| Kwak, SH | 1 |
| Choi, SH | 1 |
| Kim, K | 1 |
| Jung, HS | 1 |
| Cho, YM | 1 |
| Lim, S | 1 |
| Cho, NH | 1 |
| Kim, SY | 1 |
| Park, KS | 1 |
| Jang, HC | 1 |
| Burstein, HJ | 1 |
| Demetri, GD | 1 |
| Mueller, E | 1 |
| Sarraf, P | 1 |
| Spiegelman, BM | 1 |
| Winer, EP | 1 |
| Shimizu, K | 1 |
| Shiratori, K | 1 |
| Kobayashi, M | 1 |
| Kawamata, H | 1 |
| Xiang, AH | 2 |
| Peters, RK | 2 |
| Kjos, SL | 2 |
| Ochoa, C | 2 |
| Marroquin, A | 2 |
| Goico, J | 2 |
| Tan, S | 1 |
| Wang, C | 1 |
| Azen, SP | 1 |
| Liu, CR | 2 |
| Liu, CH | 2 |
| Hodis, HN | 3 |
| Buchanan, TA | 3 |
| Reamy, BV | 1 |
| Florez, JC | 1 |
| Jablonski, KA | 1 |
| Sun, MW | 1 |
| Bayley, N | 1 |
| Kahn, SE | 1 |
| Shamoon, H | 1 |
| Hamman, RF | 1 |
| Knowler, WC | 1 |
| Nathan, DM | 1 |
| Altshuler, D | 1 |
| Zheng, L | 1 |
| Li, Y | 1 |
| Mack, WJ | 1 |
| Kawakubo, M | 1 |
| Sakurai, A | 1 |
| Hashizume, K | 1 |
| Goss, G | 1 |
| Demetri, G | 1 |
| Caldwell, SH | 1 |
| Hespenheide, EE | 1 |
| von Borstel, RW | 1 |
| Haneda, M | 1 |
| Koya, D | 1 |
| Kikkawa, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| Diabetes Prevention Program Outcomes Study[NCT00038727] | Phase 3 | 2,779 participants (Actual) | Interventional | 2002-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level >= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose >= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test). (NCT00038727)
Timeframe: Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).
| Intervention | diabetes incidence (cases per 100 person (Number) |
|---|---|
| 1 Original Lifestyle | 5.3 |
| 2 Original Metformin | 6.4 |
| 3 Original Placebo | 7.8 |
All cause-mortality through clinic reports and National Death Index search (NCT00038727)
Timeframe: Outcomes were assessed throughout follow-up from 1996 to 2022. National Death Index search conducted in 2019 using early release data as of Dec 2018.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Original Lifestyle | 158 |
| 2 Original Metformin | 152 |
| 3 Original Placebo | 143 |
Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (<45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (> 30mg/gm, confirmed). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | average percentage of participants (Number) |
|---|---|
| 1 Original Lifestyle | 11.3 |
| 2 Original Metformin | 13 |
| 3 Original Placebo | 12.4 |
Measured using coronary artery calcification (CAC). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | CAC geometric mean in AU (Geometric Mean) | |
|---|---|---|
| Men | Women | |
| 1 Original Lifestyle | 70.1 | 6.0 |
| 2 Original Metformin | 40.2 | 6.1 |
| 3 Original Placebo | 63.7 | 5.3 |
1 review available for troglitazone and Disease Exacerbation
| Article | Year |
|---|---|
Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care.
Topics: Chromans; Combined Modality Therapy; Disease Progression; Fatal Outcome; Humans; Liposarcoma; Male; | 2000 |
6 trials available for troglitazone and Disease Exacerbation
| Article | Year |
|---|---|
Use of a Metabolic Syndrome Severity
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progress | 2018 |
Use of a Metabolic Syndrome Severity
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progress | 2018 |
Use of a Metabolic Syndrome Severity
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progress | 2018 |
Use of a Metabolic Syndrome Severity
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progress | 2018 |
Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Chromans; Disease Progre | 2003 |
Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes.
Topics: Adult; Arteriosclerosis; Carotid Arteries; Chromans; Diabetes Mellitus, Type 2; Disease Progression; | 2005 |
Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.
Topics: Amino Acid Substitution; Chromans; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Disease Progr | 2007 |
Effect of antihypertensive therapy on progression of carotid intima-media thickness in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Carotid Artery Diseases; Carotid Artery, Commo | 2007 |
Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes.
Topics: Adult; Carotid Artery Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease | 2008 |
6 other studies available for troglitazone and Disease Exacerbation
| Article | Year |
|---|---|
Prediction of type 2 diabetes in women with a history of gestational diabetes using a genetic risk score.
Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease Progression; Female; Foll | 2013 |
Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPARgamma-independent mechanism.
Topics: Actins; Animals; Cell Division; Cells, Cultured; Chromans; Chronic Disease; Disease Progression; Dru | 2004 |
Preventing the progression of diabetes mellitus.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Disease Progression; Humans; Hypoglycemic Agents; Inf | 2005 |
Deterioration of rheumatoid arthritis with troglitazone: a rare and unexpected adverse effect.
Topics: Arthritis, Rheumatoid; Chromans; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Hyp | 2000 |
Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin.
Topics: Aged; Anticholesteremic Agents; Antioxidants; Chemical and Drug Induced Liver Injury; Chromans; Diab | 2001 |
Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diacylglycerol Kinase; Disease | 2001 |